CASI Pharmaceuticals (FRA:ENM) Accounts Payable & Accrued Expense : €7.86 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Accounts Payable & Accrued Expense?

CASI Pharmaceuticals's quarterly accounts payable & accrued expense increased from Sep. 2023 (€11.08 Mil) to Dec. 2023 (€12.34 Mil) but then declined from Dec. 2023 (€12.34 Mil) to Mar. 2024 (€7.86 Mil).

CASI Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2021 (€10.27 Mil) to Dec. 2022 (€12.76 Mil) but then declined from Dec. 2022 (€12.76 Mil) to Dec. 2023 (€12.34 Mil).

CASI Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

The historical data trend for CASI Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Accounts Payable & Accrued Expense Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

7.15

4.72

10.27

12.76

12.34

CASI Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															13.11	10.99	11.08	12.34	7.86

CASI Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines